Home
Novo Nordisk Announces Significant Reduction in US List Price for Wegovy®, Ozempic® and Rybelsus®, Building on Continued Efforts to Expand Access

Novo Nordisk Announces Significant Reduction in US List Price for Wegovy®, Ozempic® and Rybelsus®, Building on Continued Efforts to Expand Access

Today’s Highlights February 24, 2026

Novo Nordisk in the NEWS

February 24, 2026 – Novo Nordisk (NVO) announced that, effective January 1, 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy® (semaglutide) injection 2.4 mg and tablets 25 mg, Ozempic® (semaglutide) injection 0.5 mg, 1 mg, and . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
February 24, 2026

Other Articles